Press "Enter" to skip to content

India’s Serum says produced 40 million doses of AstraZeneca COVID-19 vaccine

BENGALURU (Reuters) – Serum Institute of India, the world’s largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca’s potential COVID-19 vaccine, and would soon begin making Novavax’s rival shot, as they both seek regulatory approval.

While there are no COVID-19 vaccines approved yet and trials are still under way to prove they are safe and effective, leading drugmakers have been funded to begin production early to expedite deliveries, as the pandemic has killed more than 1.2 million people worldwide.

AstraZeneca AZN.L said last week that it was holding back deliveries of its COVID-19 vaccine candidate while it awaits the data from late-stage clinical trials, which got delayed due to a summer dip in UK coronavirus infections.

Serum declined to comment on whether the 40 million doses of the AstraZeneca vaccine were meant for global supply or only for India.

For production of the Novavax NVAX.O vaccine, Serum said it has received the bulk of the vaccine from the U.S. company and will soon fill and finish them in vials. Read from source….